Reductively Responsive siRNA-Conjugated Hydrogel Nanoparticles for Gene Silencing

Citations Over TimeTop 10% of 2012 papers

Abstract

A critical need still remains for effective delivery of RNA interference (RNAi) therapeutics to target tissues and cells. Self-assembled lipid- and polymer-based systems have been most extensively explored for transfection with small interfering RNA (siRNA) in liver and cancer therapies. Safety and compatibility of materials implemented in delivery systems must be ensured to maximize therapeutic indices. Hydrogel nanoparticles of defined dimensions and compositions, prepared via a particle molding process that is a unique off-shoot of soft lithography known as particle replication in nonwetting templates (PRINT), were explored in these studies as delivery vectors. Initially, siRNA was encapsulated in particles through electrostatic association and physical entrapment. Dose-dependent gene silencing was elicited by PEGylated hydrogels at low siRNA doses without cytotoxicity. To prevent disassociation of cargo from particles after systemic administration or during postfabrication processing for surface functionalization, a polymerizable siRNA pro-drug conjugate with a degradable, disulfide linkage was prepared. Triggered release of siRNA from the pro-drug hydrogels was observed under a reducing environment while cargo retention and integrity were maintained under physiological conditions. Gene silencing efficiency and cytocompatibility were optimized by screening the amine content of the particles. When appropriate control siRNA cargos were loaded into hydrogels, gene knockdown was only encountered for hydrogels containing releasable, target-specific siRNAs, accompanied by minimal cell death. Further investigation into shape, size, and surface decoration of siRNA-conjugated hydrogels should enable efficacious targeted in vivo RNAi therapies.

Related Papers

• → PEGYLATION: an important approach for novel drug delivery system(2020)144 cited
• → Pegylation and Its Impact on the Design of New Protein-Based Medicines(2014)89 cited
• → Short Interfering RNA (siRNA)—Mediated RNA Interference (RNAi) in Human Cells(2003)82 cited
• → Can siRNA Technology Provide the Tools for Gene Therapy of the Future?(2006)34 cited
• 포스터발표 2 : 생명공학 ; P-437 : 재조합 인터페론-알파-2a의 재생을 위한 고체상 PEGylation과 재접힘의 통합 공정(2007)